DAVENPORT & Co LLC reduced its position in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 86.4% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,700 shares of the company's stock after selling 138,440 shares during the quarter. DAVENPORT & Co LLC's holdings in Roivant Sciences were worth $219,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also modified their holdings of ROIV. Norges Bank bought a new position in shares of Roivant Sciences in the fourth quarter worth approximately $52,443,000. Invesco Ltd. boosted its position in shares of Roivant Sciences by 49.7% in the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock worth $112,563,000 after purchasing an additional 3,159,603 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Roivant Sciences by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares in the last quarter. TOMS Capital Investment Management LP lifted its holdings in shares of Roivant Sciences by 46.6% in the fourth quarter. TOMS Capital Investment Management LP now owns 5,885,000 shares of the company's stock worth $69,620,000 after buying an additional 1,870,000 shares in the last quarter. Finally, Marshall Wace LLP lifted its holdings in shares of Roivant Sciences by 104.4% in the fourth quarter. Marshall Wace LLP now owns 2,946,954 shares of the company's stock worth $34,862,000 after buying an additional 1,505,062 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have recently commented on ROIV shares. HC Wainwright reissued a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Wednesday, June 18th. The Goldman Sachs Group raised shares of Roivant Sciences to a "strong-buy" rating and set a $19.00 target price on the stock in a report on Thursday.
Check Out Our Latest Stock Analysis on ROIV
Roivant Sciences Price Performance
Shares of ROIV stock traded down $0.21 during mid-day trading on Friday, hitting $11.36. The company had a trading volume of 5,078,323 shares, compared to its average volume of 5,758,784. The stock's 50 day moving average price is $11.11 and its 200-day moving average price is $10.86. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.15). The business had revenue of $7.57 million for the quarter, compared to analysts' expectations of $62.17 million. Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. During the same period in the previous year, the company earned ($0.23) EPS. On average, equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, COO Eric Venker sold 100,000 shares of the company's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.45, for a total transaction of $1,145,000.00. Following the sale, the chief operating officer owned 1,462,223 shares of the company's stock, valued at $16,742,453.35. This represents a 6.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Vivek Ramaswamy sold 577,007 shares of the company's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $11.46, for a total transaction of $6,612,500.22. Following the sale, the insider directly owned 37,284,108 shares in the company, valued at approximately $427,275,877.68. The trade was a 1.52% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 3,464,462 shares of company stock worth $39,098,856. 7.90% of the stock is owned by insiders.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
